Moderna, Inc.

Company Overview

Business Model: Moderna, Inc. is a biotechnology company focused on advancing messenger RNA (mRNA) medicine. Its core value proposition is to direct the body's cells to produce intracellular, membrane, or secreted proteins for therapeutic or preventive benefits across a broad spectrum of diseases. The Company's primary revenue generation mechanisms include the commercialization of approved mRNA vaccines and therapeutics, as well as strategic collaborations and grant funding for research and development.

Market Position: Moderna, Inc. is a pioneer and leader in the field of mRNA medicine, leveraging its technology platform for vaccine and therapeutic candidates across infectious disease, oncology, and rare disease. The Company currently has three commercial products: Spikevax and mNEXSPIKE (COVID vaccines), and mRESVIA (respiratory syncytial virus (RSV) vaccine). In the U.S. retail channel, mNEXSPIKE, launched in Q3 2025, is now the leading product. The Company faces intense competition in the vaccine and pharmaceutical markets, particularly from larger, well-established companies like Pfizer Inc., BioNTech SE, Sanofi, and GlaxoSmithKline Biologicals SA.

Recent Strategic Developments:

• Product Launches & Approvals: mNEXSPIKE (COVID vaccine) was commercially launched in Q3 2025 in the U.S. and approved in Europe, Canada, and Australia. mRESVIA (RSV vaccine) received FDA approval in May 2024 for adults 60+ and expanded approval in June 2025 for adults 18-59 at increased risk.
• Pipeline Advancement: Five-year data from the Phase 2b study of intismeran autogene (mRNA-4157) in combination with Merck’s pembrolizumab demonstrated sustained improvement in recurrence-free survival in high-risk melanoma patients (January 2026). Regulatory filings for seasonal flu+COVID combination vaccine (mRNA-1083) are under review in Europe and Canada, and for seasonal flu vaccine (mRNA-1010) in the U.S., Europe, Canada, and Australia (U.S. PDUFA goal date: August 5, 2026).
• Manufacturing Expansion: New drug product capabilities in the U.S. were announced in 2025, with construction at the Moderna Technology Center in Norwood, Massachusetts, targeting completion in H1 2027 for end-to-end mRNA manufacturing. Three Moderna-built and managed facilities in the UK, Canada, and Australia were fully licensed in 2025, enabling local access to mRNA vaccines and supporting multi-year government commitments. The Marlborough, Massachusetts facility, purpose-built for intismeran autogene, began clinical batch supply in September 2025.
• Strategic Collaborations: Entered a strategic collaboration with Recordati in January 2026 to advance mRNA-3927 (propionic acidemia therapeutic) through clinical development and global commercialization. CEPI committed up to $54.3 million in December 2025 to support a pivotal Phase 3 clinical trial for mRNA-1018 (H5 pandemic influenza vaccine candidate).
• Cost Efficiency: Maintained disciplined cost management throughout 2025, improving productivity across manufacturing, R&D, and SG&A, with further reductions expected in 2026 and 2027.

Geographic Footprint: Moderna, Inc. has active commercial subsidiaries in key markets across North America, Europe, and the Asia-Pacific region. Its primary operational regions include the United States (headquarters in Cambridge, MA, manufacturing in Norwood and Marlborough, MA), Canada (manufacturing in Laval, Quebec), the UK (manufacturing and R&D in Oxfordshire), and Australia (manufacturing in Clayton, Victoria). The Company also engages with third-party distributors and commercial alliances in countries where it does not have a direct presence.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 55.3% (2025) vs. 54.7% (2024)
• Operating Margin: -158.1% (2025) vs. -121.9% (2024)
• Net Margin: -145.2% (2025) vs. -111.5% (2024)

Investment in Growth:

• R&D Expenditure: $3,132 million (161.1% of revenue)
• Capital Expenditures: $192 million
• Strategic Investments: Acquisition of Moderna Technology Center campus for $385 million in December 2024. Upfront payment of $120 million to Immatics N.V. in October 2023 for a strategic collaboration. CEPI investment of up to $54.3 million in December 2025 to support a pivotal Phase 3 clinical trial for mRNA-1018.

Key Pipeline Developments

Moderna, Inc. is advancing a diverse development pipeline consisting of 35 therapeutic and vaccine programs, with 6 in late-stage development, across three franchises: infectious disease vaccines, oncology therapeutics, and rare disease therapeutics.

Infectious Disease Franchise

Respiratory Vaccines:

• COVID vaccines (Spikevax, mNEXSPIKE): Spikevax 2025-2026 formula approved in 40 countries. mNEXSPIKE 2025-2026 formula approved by FDA for individuals 65+ and 12-64 at high risk; also approved in Europe, Canada, and Australia.
• RSV vaccine (mRESVIA): Approved in 40 countries for adults 60+ and in 31 of those countries for high-risk adults 18-59. Phase 3 studies show immune response restoration upon revaccination, co-administration with COVID mRNA vaccine, and immunogenicity in solid organ transplant population.
• Seasonal influenza vaccine (mRNA-1010): Regulatory filings under review in U.S., Europe, Canada, and Australia. Amended BLA accepted by FDA in February 2026 with a PDUFA goal date of August 5, 2026, seeking full approval for adults 50-64 and accelerated approval for adults 65+. Phase 3 study results in October 2025 showed 26.6% relative vaccine efficacy versus standard dose comparator in adults 50+.
• Combination vaccines (mRNA-1083): Seasonal flu+COVID combination vaccine under regulatory review in Europe and Canada. Phase 3 clinical trial met primary endpoints in June 2024, eliciting higher immune responses against influenza and SARS-CoV-2 than licensed vaccines.
• Pandemic influenza vaccine (mRNA-1018): Phase 1/2 study results in October 2025 showed rapid, potent, and durable immune response. Phase 3 trial expected to begin in early 2026 with CEPI funding.

Latent and Other Vaccines:

• CMV vaccine (mRNA-1647): Phase 2 proof-of-concept study in allogeneic hematopoietic cell transplant (HCT) patients is ongoing, showing robust CMV-specific T-Cell responses. The congenital CMV program was discontinued in October 2025 after failing its primary clinical endpoint.
• EBV vaccines (mRNA-1189, mRNA-1195): Phase 2 studies ongoing for prophylactic vaccine (mRNA-1189) and therapeutic for multiple sclerosis (mRNA-1195). Phase 1 data for both showed immunogenicity and general tolerability.
• Norovirus vaccines (mRNA-1403): Phase 3 study of trivalent vaccine candidate mRNA-1403 completed its first seasons in Northern and Southern Hemispheres, with a second Northern Hemisphere season cohort fully enrolled. Phase 1 data showed robust antibody responses.
• Lyme vaccines (mRNA-1975, mRNA-1982): Phase 1/2 trial ongoing for heptavalent (mRNA-1975) and monovalent (mRNA-1982) approaches. mRNA-1982 will progress to a Phase 2 dose-ranging study.
• Nipah vaccine (mRNA-1215): Phase 1 clinical trial completed in collaboration with NIH-Vaccine Research Center.
• Mpox vaccine (mRNA-1769): Phase 1/2 interim analysis showed favorable safety profile and strong immunogenicity, with full study results expected in 2026.

Oncology Therapeutics Franchise

• Intismeran autogene (mRNA-4157): Developed in collaboration with Merck. Eight Phase 2 and Phase 3 clinical trials are underway across multiple tumor types (melanoma, NSCLC, bladder cancer, renal cell carcinoma). Five-year data from Phase 2b study in high-risk melanoma showed sustained 49% reduction in recurrence or death risk. Received Breakthrough Therapy Designation from FDA (February 2023) and PRIME Scheme Designation from EMA (April 2023).
• Cancer antigen therapy (mRNA-4359): Wholly-owned investigational therapy. Phase 1b study data in 2025 showed 24% objective response rate in checkpoint inhibitor resistant/refractory melanoma patients in combination with pembrolizumab. Phase 2 portion of study ongoing in metastatic melanoma and NSCLC, with potential data readout in 2026.
• Early-stage oncology programs: mRNA-4106 (cancer antigen therapy, Phase 1 commenced 2025), mRNA-2808 (T-cell engager, Phase 1/2 ongoing), mRNA-4203 (cell-therapy enhancer with Immatics N.V., Phase 1 commenced 2025).

Rare Disease Franchise

• Propionic acidemia (mRNA-3927): Registrational study has reached target enrollment. Strategic collaboration with Recordati initiated in January 2026 for final clinical development and global commercialization. Received Rare Pediatric Disease Designation, Orphan Drug Designation, and Fast Track Designation from FDA, and Orphan Designation from European Commission.
• Methylmalonic acidemia (mRNA-3705): Selected by FDA for the START program. Registrational study expected to begin in 2026. Phase 1/2 study showed encouraging initial data with reductions in biomarkers.
• Cystic Fibrosis (mRNA-3692/VX-522): In collaboration with Vertex Pharmaceuticals Incorporated. Phase 1/2 study underway, with data expected in H2 2026. FDA granted Fast Track designation.

Programs Discontinued in 2025: mRNA-1647 (CMV in congenital CMV), mRNA-1608 (Herpes simplex virus vaccine), mRNA-1468 (Varicella-Zoster virus vaccine), mRNA-3745 (Glycogen Storage Disease Type 1a therapeutic), mRNA-3210 (Phenylketonuria therapeutic).

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: No shares repurchased during the three months ended December 31, 2025. As of December 31, 2025, $1.7 billion of the $6.0 billion share repurchase program authorization remained outstanding.
• Dividend Payments: Moderna, Inc. has never declared or paid cash dividends on its common stock and does not expect to pay dividends for the foreseeable future.
• Dividend Yield: N/A
• Future Capital Return Commitments: $1.7 billion remaining authorization for share repurchases.

Balance Sheet Position:

• Cash and Equivalents: $2,595 million (as of December 31, 2025)
• Total Debt: $590 million (as of December 31, 2025, net of unamortized original issue discount and debt issuance costs)
• Net Cash Position: $2,005 million
• Credit Rating: Not disclosed in the filing.
• Debt Maturity Profile: In November 2025, Moderna, Inc. entered into a $1.5 billion senior secured term loan facility. An initial term loan of $600 million was funded at closing and matures on November 24, 2030. The facility includes $900 million of delayed draw term loan commitments, with $400 million available through November 2027 and $500 million available through November 2028 (subject to regulatory approval milestones). The initial term loan bears interest at a variable rate (approximately 9.38% as of December 31, 2025).

Cash Flow Generation:

• Operating Cash Flow: $(1,873) million (for the year ended December 31, 2025)
• Free Cash Flow: $(2,065) million (Operating Cash Flow of $(1,873) million minus Capital Expenditures of $192 million for the year ended December 31, 2025)
• Cash Conversion Metrics: Not explicitly detailed in the filing.

Operational Excellence

Production & Service Model: Moderna, Inc. employs a novel and complex mRNA manufacturing process, utilizing a cell-free in vitro transcription approach. The Company invests in proprietary purification techniques and LNP systems designed for optimal delivery and expression. Its operational philosophy emphasizes high-throughput automation, robotics, and state-of-the-art digital integration to improve efficiency, scale, and quality across all stages from discovery to commercialization.

Supply Chain Architecture: Key Suppliers & Partners:

• Raw Materials & Components: Dependent on single-source suppliers for some critical components and materials.
• Manufacturing Partners: Utilizes Contract Manufacturing Organizations (CMOs) in the United States and internationally for raw material production and fill-finish capacity for vaccines.
• Distribution Partners: Leverages third-party wholesalers and integrates with artificial intelligence-driven data analytics for direct-to-customer shipments of commercial products.

Facility Network:

• Manufacturing:
  • Moderna Technology Center (Norwood, Massachusetts): Dedicated in-house, multi-building campus (approx. 722,000 sq ft) acquired in December 2024. Supports preclinical research, IND-enabling GLP toxicology studies, Phase 1 and Phase 2 pipeline activities, later-stage clinical development, and drug substance commercial production for vaccines. Construction for new commercial drug product manufacturing and packaging capability commenced in 2025, targeting completion in H1 2027.
  • Marlborough, Massachusetts Facility: Acquired in Q2 2023, expanded to 140,000 sq ft, purpose-built for intismeran autogene. Became operational in August 2025 and began shipping clinical patient batches in September 2025.
  • Laval, Quebec, Canada Facility: Owned, completed construction in September 2024, fully licensed in 2025. Approx. 100,000 sq ft, capacity up to 100 million doses annually. Began manufacturing Spikevax drug substance in 2025 and approved for mRESVIA production in December 2025.
  • Moderna Technology Centre – Melbourne (Clayton, Victoria, Australia): Owned, approx. 130,000 sq ft, GMP licensed in August 2025. Designed for end-to-end mRNA vaccine manufacturing, capacity up to 100 million doses annually.
  • Moderna Innovation and Technology Centre (Oxfordshire, United Kingdom): Owned, opened in September 2025, approx. 100,000 sq ft. Capacity up to 100 million doses annually, expandable to 250 million doses in a pandemic. Supports mRNA vaccine manufacturing and related research.
• Research & Development: Moderna Science Center (Cambridge, Massachusetts) serves as the principal executive office and location for corporate headquarters, platform, drug discovery, and clinical development activities. The MITC in the UK also supports R&D.
• Distribution: Utilizes third-party wholesalers and AI-driven data analytics for direct-to-customer shipments.

Operational Metrics:

• Manufacturing Capacity: Canadian, Australian, and UK facilities each have a capacity of up to 100 million doses annually, with the UK facility expandable to approximately 250 million doses in a pandemic.
• Intismeran Autogene Turnaround: Proprietary bioinformatics algorithms and automated manufacturing processes enable rapid production of formulated mRNA, with a typical turnaround time of a few weeks from sequencing tumor samples to patient-specific batch delivery.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Maintains local commercial teams in major markets across North America, Europe, and Asia-Pacific.
• Channel Partners: Works with third-party distributors and other commercial alliances in countries without a direct presence.
• Digital Platforms: Leverages online sales channels and e-commerce initiatives, supported by AI-driven data analytics, to enhance commercial capabilities and speed to market.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: Sales primarily to wholesalers and distributors in the U.S., and to foreign governments and international organizations globally.
• Strategic Partnerships: Long-term strategic agreements with governments in the UK, Canada, and Australia for mRNA product purchases and manufacturing readiness.
• Customer Concentration:
  • For the year ended December 31, 2025, FFF Enterprises accounted for 15% of total revenue, Public Works and Government Services Canada for 13%, and Cardinal Health for 11%.
  • For the year ended December 31, 2024, United Kingdom Health Security Agency accounted for 16% of total revenue.
  • As of December 31, 2025, Mexico Medistik accounted for 29% of accounts receivable, and Boryung Biopharma Korea for 17%.
  • As of December 31, 2024, United Kingdom Health Security Agency accounted for 65% of accounts receivable.

Geographic Revenue Distribution:

• United States: $1,199 million (61.7% of total revenue in 2025)
• Europe: $53 million (2.7% of total revenue in 2025)
• Rest of world: $692 million (35.6% of total revenue in 2025)

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on intellectual property defense. The mRNA field is experiencing rapid growth, leading to increased competitive pressure from large and established pharmaceutical companies. The oncology market, in particular, is intensely competitive, innovative, and fast-moving, with rapidly evolving standards of care.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Pfizer Inc. and BioNTech SE: Primary competitors for COVID vaccines, also based on mRNA technology. Involved in ongoing patent litigation.
• Sanofi and Novavax: Other competitors in the COVID vaccine market.
• GlaxoSmithKline Biologicals SA: Competitor in the RSV vaccine market, having entered prior to Moderna, Inc. Also involved in patent litigation.
• Other Pharmaceutical and Biotechnology Companies: Numerous companies, academic institutions, government agencies, and research organizations developing products across infectious disease, oncology, and rare disease.

Emerging Competitive Threats: New entrants, disruptive technologies, and alternative solutions (e.g., Pfizer Inc.'s antiviral pill for COVID) pose competitive threats. The rapid evolution of oncology markets and new standards of care could reduce clinical relevance or limit commercial adoption of Moderna, Inc.'s product candidates.

Competitive Response Strategy: Moderna, Inc. aims to maintain its competitive advantage by driving sales growth through geographic expansion and new product launches, delivering cost efficiency across the business, executing on its prioritized pipeline, and continuing to advance its early pipeline and platform technology. The Company leverages its mRNA platform's breadth of applicability and shared manufacturing processes to accelerate discovery and development.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: Regulatory and market uncertainty, including evolving FDA, CDC, and Advisory Committee on Immunization Practices (ACIP) recommendations, viral evolution, and consumer motivation, may impact demand for vaccines. Difficulties in accurately forecasting vaccination rates and competitive pricing pressure could affect product sales.
• Technology Disruption: The rapid growth of the mRNA field and the broader pharmaceutical market means competitors may develop superior products or technologies, potentially rendering Moderna, Inc.'s products obsolete.
• Customer Concentration: Sales of pharmaceutical products depend on the availability and extent of reimbursement from third-party payors, and changes to reimbursement policies or rules (e.g., federal legislative efforts like "most-favored-nation" pricing) could adversely impact product revenues.
• Execution of Strategy: Difficulties in executing the near-term strategy and prioritized pipeline, including commercializing new products and achieving cost efficiency goals, could impact investment in oncology and rare disease programs.

Operational & Execution Risks

• Supply Chain Vulnerabilities: Manufacturing processes for mRNA medicines are novel and complex, leading to potential difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management, or shipping. Dependence on single-source suppliers for some components and materials creates risks of disruptions, price increases, or late deliveries.
• Geographic Concentration: Expansion of global manufacturing and operational footprint (e.g., new facilities in UK, Canada, Australia) introduces risks associated with managing costs, operational complexity, and regulatory requirements in diverse jurisdictions.
• Capacity Constraints: Increased demand for clinical and commercial supplies as the pipeline matures may impact the ability to operate, requiring significant investments in manufacturing networks and reliance on third parties for capacity.
• Intismeran Autogene Manufacturing: Unique manufacturing process for individualized neoantigen therapies is susceptible to product loss or failure due to logistics, sequencing, software design, batch-specific issues, quality control, and cost.
• Operational Risks: High level of automation and digital integration in manufacturing facilities exposes the Company to risks of process equipment malfunctions, system failures, cybersecurity incidents, and physical intrusions.

Financial & Regulatory Risks

• Market & Financial Risks: Moderna, Inc. incurred net losses in 2025 and 2024 and expects additional losses, impacting long-term profitability. Quarterly and annual operating results may fluctuate due to various factors, potentially causing stock price decline. Investments in cash, cash equivalents, and marketable securities are subject to credit, liquidity, market, inflation, and interest rate risks.
• Credit & Liquidity: Failure to comply with covenants in the credit agreement could result in an event of default, adversely affecting the business.
• IP Litigation: Uncertainty over intellectual property in the pharmaceutical and biotechnology industry has led to costly and unpredictable litigation and patent office proceedings, which can have adverse financial and freedom-to-operate consequences.
• Regulatory & Compliance Risks: Products are subject to extensive and evolving government regulation (FDA, EMA, etc.) for research, development, manufacture, and marketing. Failure to obtain or delays in obtaining regulatory approvals and advisory committee recommendations can hinder commercialization. Post-approval products remain subject to scrutiny, including adverse event reporting, pharmacovigilance, and potential post-approval studies.
• Healthcare Laws: Subject to federal and state healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act, HIPAA, Physician Payments Sunshine Act) and foreign anti-bribery regulations (e.g., FCPA, UK Bribery Act). Non-compliance could lead to substantial penalties.
• Data Privacy: Subject to various and evolving laws and regulations governing privacy and security of personal data (e.g., EU GDPR, UK GDPR, CCPA), with non-compliance potentially resulting in fines, criminal penalties, and reputational damage.

Geopolitical & External Risks

• Geopolitical Exposure: Risks associated with doing business outside the United States, including regulatory compliance, political/cultural/economic changes, IP protection, trade-protection measures, foreign tax structures, and currency exchange rate fluctuations.
• Trade Relations: Changes in tariffs and other governmental trade policies could negatively affect business and results of operations by increasing supply costs or causing delays.
• Economic Conditions: Unfavorable U.S. or global economic conditions (e.g., inflation, rising interest rates, recession, war, conflict) could adversely affect demand for medicines, ability to raise capital, and supplier stability.
• Climate Change: Exposed to physical risks (e.g., severe storms), transition risks (e.g., new regulations, carbon pricing), and social impacts, which could disrupt operations, increase costs, and affect the supply chain.

Innovation & Technology Leadership

Research & Development Focus: Moderna, Inc.'s R&D is centered on its mRNA platform, which integrates advances across mRNA science, delivery science, and manufacturing processes.

• Core Technology Areas:
  • mRNA Science: Focuses on modified nucleotides to mitigate immune system activation, sequence engineering to maximize protein expression, and targeting elements (e.g., microRNA binding sites) to enable tissue-targeted translation.
  • Delivery Science: Develops proprietary Lipid Nanoparticle (LNP) technologies, including novel amino lipid chemistry for improved safety and tolerability, optimized LNP composition for enhanced delivery efficiency, and LNP surface properties designed to avoid immune recognition and enable sustained pharmacology upon repeat dosing.
  • Manufacturing Process Science: Invests in cell-free in vitro transcription for mRNA production, proprietary purification techniques, and synthetic processes for LNP manufacturing, with a focus on improving pharmacology, efficiency, and potency.
• Innovation Pipeline: The Company has a diverse pipeline of 35 therapeutic and vaccine programs, with 6 in late-stage development, spanning infectious disease, oncology, and rare disease. This includes early-stage oncology programs (cancer antigen therapies, T-cell engagers, cell-therapy enhancers) and multiple early-stage vaccine programs.

Intellectual Property Portfolio:

• Patent Strategy: Moderna, Inc. has built a substantial, multi-layered IP estate to protect its platform, modalities, and programs. This includes over 260 issued or allowed U.S. patents/applications and over 140 granted or allowed foreign patents, with 485 additional pending patent applications. Most patents expire no earlier than 2033, with recent filings projected to expire between 2044 and 2045. The portfolio covers mRNA design, LNP components, delivery systems, manufacturing processes, and analytical methods.
• Licensing Programs:
  • Cellscript, LLC and mRNA RiboTherapeutics, Inc.: Sublicense agreements for Penn Modified mRNA Patents, requiring low single-digit royalties on net sales.
  • National Institute of Allergy and Infectious Diseases (NIAID): Non-exclusive patent license agreements for coronavirus spike proteins (low single-digit royalties) and prefusion RSV F proteins (tiered low-to-mid single-digit royalties).
• IP Litigation: Actively involved in patent infringement litigation with Pfizer Inc./BioNTech SE, Arbutus Biopharma Corporation/Genevant Sciences GmbH, GlaxoSmithKline Biologicals SA, Northwestern University, Bayer CropScience LLC, mNG Bio, LLC, and BioNTech SE, concerning various aspects of its mRNA platform and vaccine designs.
• Trade Secrets: Relies on trade secrets, know-how, and technology related to its proprietary technology and programs, including manufacturing processes and expertise.

Technology Partnerships: Collaborates with a diverse group of entities, including Merck for intismeran autogene, Vertex Pharmaceuticals Incorporated for cystic fibrosis, Immatics N.V. for oncology therapeutics, and government agencies like CEPI, BARDA, and the Gates Foundation for various development projects.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The Company conducts periodic talent reviews to identify key talent and inform development opportunities for current and potential future leaders, supporting succession planning activities for key roles. Board Composition: Not explicitly detailed in the provided filing.

Human Capital Strategy

Workforce Composition:

• Total Employees: Approximately 4,700 full-time employees as of December 31, 2025.
• Geographic Distribution: Employees located in 18 countries.
• Skill Mix: 46% of employees hold Ph.D., Doctorate, M.D., J.D., or Master’s degrees as of December 31, 2025.
• Diversity: 49% of employees are female. Approximately 39% of leadership (Vice President level and above) are female. 44% of U.S. employees identify as racially or ethnically diverse.

Talent Management: Acquisition & Retention:

• Hiring Strategy: Operates in a highly competitive environment for talent, particularly in biotechnology and pharmaceuticals.
• Retention Metrics: Voluntary turnover rate was approximately 11% in 2025.
• Employee Value Proposition: Focuses on providing purpose, growth, well-being, belonging, and compelling rewards, including competitive compensation and equity programs for all employees (with the percentage of equity increasing with seniority).
• Employee Engagement: Measures employee engagement through vendor-supplied software and external benchmarks.

Diversity & Development:

• Development Programs: Offers a structured training curriculum, online library of scientific material, and management/leadership trainings. Launched an AI Academy in December 2021 to educate and empower employees to integrate AI and machine learning solutions.
• Culture & Engagement: Values include being bold, collaborative, curious, and relentless, underpinned by integrity, quality, and respect. The "Moderna Mindsets" define behavior, leadership, and decision-making, integrated into talent identification, onboarding, growth, and management.

Environmental & Social Impact

Environmental Commitments: Climate Strategy: Moderna, Inc. has established a global Environment, Health, and Safety (EHS) organization to foster a safe and healthy work environment with a focus on sustainability and compliance. This approach integrates environmentally responsible practices with health and safety measures. Supply Chain Sustainability: Not explicitly detailed in the provided filing.

Social Impact Initiatives: Moderna, Inc. has developed a corporate social responsibility (CSR) program with five key focus areas: medicines for patients, community, governance and ethics, employees, and environment. The Company's employees have opportunities to give back to communities through volunteer and employee matching donation programs.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: The commercial markets for Moderna, Inc.'s COVID and RSV vaccines are seasonal, characterized by unpredictability in orders and seasonality of deliveries.
• Economic Sensitivity: The respiratory vaccine market, particularly for COVID and RSV vaccines, depends on factors such as medical need, viral evolution, public health authority recommendations, and consumer motivation to vaccinate. The Company experienced a decline in customer demand for its COVID vaccine in 2023, 2024, and 2025 as the market transitioned to a more competitive and commercially driven environment.
• Industry Cycles: Not explicitly detailed beyond respiratory vaccines.

Planning & Forecasting: Forecasting demand for COVID vaccines requires advance production planning ahead of each season, including production of multiple COVID vaccine products.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• United States: Regulated by the FDA under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act. Product candidates require approval through a Biologics License Application (BLA) or New Drug Application (NDA). Subject to preclinical (GLP) and clinical (GCP) study requirements, including Phase 1, 2, and 3 trials. Expedited development and review programs (Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review) are utilized. Emergency Use Authorizations (EUA) may be granted during public health emergencies (EUA for COVID vaccine revoked August 2025). The Public Readiness and Emergency Preparedness Act (PREP Act) provides liability immunity for covered countermeasures. Pediatric information requirements (PREA, BPCA) and Rare Pediatric Disease Designation (RPDD) with potential Priority Review Vouchers (PRV) are applicable. Post-approval requirements include adverse event reporting, pharmacovigilance, promotional restrictions, and cGMP compliance.
• European Economic Area (EEA): Medicinal products require marketing authorization from competent regulatory authorities. Clinical trials are subject to the Clinical Trials Regulation (EC) No. 536/2014. A Pediatric Investigational Plan (PIP) is required for marketing authorization applications. Marketing authorizations can be obtained via centralized, national, decentralized, or mutual recognition procedures. Conditional marketing authorizations may be granted. Innovative medicinal products qualify for 8 years of data exclusivity and 2 years of market protection. Orphan medicinal product designation provides 10 years of market exclusivity. Legislative proposals introduced in April 2023 are expected to reform the regulatory framework, with a common position agreed upon in December 2025, but not applicable before 2028.
• International Compliance: Requirements vary by country outside the U.S. and EU.

Trade & Export Controls: Subject to various laws and regulations restricting the use and dissemination outside the United States, or sharing with certain non-U.S. nationals, of classified information, products, and technical data (e.g., Export Administration Regulations). The Department of Justice’s January 2025 rule prohibits data brokerage transactions involving sensitive personal data to countries of concern.

Legal Proceedings: Moderna, Inc. is involved in significant intellectual property litigation, including:

• Pfizer Inc./BioNTech SE: Patent infringement lawsuits in the U.S., UK, Netherlands, Germany, Ireland, and Belgium concerning mRNA platform technology and vaccine designs.
• Arbutus Biopharma Corporation/Genevant Sciences GmbH: Patent infringement lawsuits in the U.S., Canada, Japan, Switzerland, and the Unified Patent Court concerning lipid nanoparticles.
• GlaxoSmithKline Biologicals SA: Patent infringement lawsuits in the U.S., Unified Patent Court, and Spanish courts concerning lipid-mRNA vaccine formulation technology.
• Northwestern University: Patent infringement lawsuit in the U.S. concerning lipid nanoparticle technology.
• Bayer CropScience LLC, Monsanto Company, and Monsanto Technology, LLC: Patent infringement lawsuit in the U.S. concerning methods of modifying gene sequences.
• mNG Bio, LLC: Patent infringement lawsuit in the U.S. concerning a yellow-green fluorescent protein.
• BioNTech SE: Patent infringement lawsuit in the U.S. concerning modified mRNA compositions encoding a spike protein fragment.
• Securities Class Action and Derivative Litigation: Putative shareholder class action and derivative complaints filed in the U.S. District Court for the District of Massachusetts related to statements about the RSV vaccine (mRNA-1345).

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: (2.0)% for 2025, 1.3% for 2024, and (19.6)% for 2023. The 2025 rate was higher than the federal statutory rate primarily due to a global valuation allowance against deferred tax assets and taxable income in certain foreign subsidiaries despite a consolidated pre-tax loss.
• Net Operating Loss (NOL) Carryforwards: As of December 31, 2025, $4.1 billion federal, $3.3 billion state, and $89 million foreign NOL carryforwards.
• Tax Credit Carryforwards: As of December 31, 2025, $111 million federal and $208 million state research and development tax credit carryforwards.
• Unrecognized Tax Benefits: $241 million of net unrecognized tax benefits as of December 31, 2025.
• Valuation Allowance: Maintained a global valuation allowance against the majority of deferred tax assets in 2025 and 2024, consistent with the assessment established in 2023 due to continued and projected losses.

Geographic Tax Planning: Not explicitly detailed in the provided filing.

Tax Reform Impact: The Company is subject to evolving and complex tax laws. Recent changes, such as the Inflation Reduction Act of 2022, and ongoing legislative proposals (e.g., regarding drug pricing) could have a material adverse effect on the business, cash flow, financial condition, and results of operations.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Maintains product liability insurance coverage, though it may not provide adequate coverage against all potential liabilities or for all claims.
• Risk Transfer Mechanisms:
  • Indemnification: Indemnifies its officers, directors, and employees for certain events. Has standard indemnification arrangements in leases and agreements with counterparties (collaborators, contractors, clinical sites, customers) for losses suffered or incurred as a result of Moderna, Inc.'s activities.
  • Statutory Immunity: The COVID vaccine benefits from liability protections under the Public Readiness and Emergency Preparedness Act (PREP Act) in the U.S. for sales during the pandemic public health emergency, though this immunity may be unavailable for future claims or sales.
  • Government Indemnification: The U.S. and certain foreign governments contractually agreed to indemnify Moderna, Inc. for sales during the pandemic public health emergency, but such indemnification or statutory immunity may be unavailable for future sales of commercial products.